bDMARD use under scrutiny in AS and PsA


An unexpected gender balance in the use of biological DMARDS for ankylosing spondylitis (AS) has piqued the curiosity of the PBAC’s Drug Utilisation Subcommittee (DUSC). While epidemiological data suggest the disease is three times more common in males than females, DUSC found that males outnumber women only two to one among patients already on biologics, ...


Already a member? Login to keep reading


OR
© 2017 the limbic